Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.

PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunological disorders. This article highlights our work toward the identification of a potent, selective, and efficacious PI3Kδ inhibitor. Through careful SAR, the successful replacement of a polar pyrazole group by a simple chloro or trifluoromethyl group led to improved Caco-2 permeability, reduced Caco-2 efflux, reduced hERG PC activity, and increased selectivity profile while maintaining potency in the CD69 hWB assay. The optimization of the aryl substitution then identified a 4'-CN group that improved the human/rodent correlation in microsomal metabolic stability. Our lead molecule is very potent in PK/PD assays and highly efficacious in a mouse collagen-induced arthritis model.

[1]  G. Schieven,et al.  Identification of highly potent and selective PI3Kδ inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[2]  C. Weigelt,et al.  Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[3]  R. Wolf,et al.  Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. , 2016, Bioorganic & medicinal chemistry letters.

[4]  C. Weigelt,et al.  Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[5]  P. Rowland,et al.  Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease. , 2016, Journal of medicinal chemistry.

[6]  J. McCarter,et al.  Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quino , 2016, Journal of medicinal chemistry.

[7]  Pascal Furet,et al.  Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. , 2016, ACS medicinal chemistry letters.

[8]  J. Herranz,et al.  ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. , 2016, Biochemical pharmacology.

[9]  J. Chandrasekhar,et al.  2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors. , 2016, Journal of medicinal chemistry.

[10]  J. McCarter,et al.  Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors. , 2016, Journal of medicinal chemistry.

[11]  P. Jones,et al.  Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. , 2015, Journal of medicinal chemistry.

[12]  J. McCarter,et al.  Synthesis and SAR study of potent and selective PI3Kδ inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[13]  Xiaolin Hao,et al.  Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. , 2015, Journal of medicinal chemistry.

[14]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[15]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[16]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[17]  Bonnie Tillotson,et al.  PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.

[18]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[19]  P. Grieco,et al.  PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. , 2012, Cardiovascular research.

[20]  P. Norman.  Selective PI3Kδ inhibitors, a review of the patent literature , 2011, Expert opinion on therapeutic patents.

[21]  E. Hirsch,et al.  Involvement of Phosphoinositide 3-Kinase &ggr; in Angiogenesis and Healing of Experimental Myocardial Infarction in Mice , 2010, Circulation research.

[22]  C. García-echeverría,et al.  Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery , 2008, Expert opinion on therapeutic targets.

[23]  T. Crabbe.  Exploring the potential of PI3K inhibitors for inflammation and cancer. , 2007, Biochemical Society transactions.

[24]  I. Adcock,et al.  Therapeutic Potential of Phosphatidylinositol 3-Kinase Inhibitors in Inflammatory Respiratory Disease , 2007, Journal of Pharmacology and Experimental Therapeutics.

[25]  C. Rommel,et al.  PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? , 2007, Nature Reviews Immunology.

[26]  R. Nussbaum,et al.  Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase , 2002, Mammalian Genome.

[27]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[28]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[29]  Sheila M. Thomas,et al.  Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement , 2005, Molecular and Cellular Biology.

[30]  A. Bilancio,et al.  Signalling by PI3K isoforms: insights from gene-targeted mice. , 2005, Trends in biochemical sciences.

[31]  P. Finan,et al.  Essential role for the p110δ phosphoinositide 3-kinase in the allergic response , 2004, Nature.

[32]  M. J. Fry,et al.  The phosphoinositide (PI) 3-kinase family , 2003, Journal of Cell Science.

[33]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[34]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[35]  L. Cantley,et al.  Phosphoinositide 3-kinase in immunological systems. , 2002, Seminars in immunology.

[36]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[37]  Silvano Sozzani,et al.  Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation , 2000 .

[38]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.